×

We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now
A sign outside the Adcock Ingram offices in Johannesburg. Picture: REUTERS
A sign outside the Adcock Ingram offices in Johannesburg. Picture: REUTERS

Adcock Ingram has posted a 6% rise in annual revenue, helped by strong demand for immune-boosting products, as well as some linked to the treatment of Covid-19.

The pharmaceutical manufacturer’s earnings, however, took a knock.

Alishia Seckam spoke to CEO Andy Hall for more detail.

Companies in this Story

subscribe

Would you like to comment on this article?
Register (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.

Commenting is subject to our house rules.